Article

Bausch + Lomb acquires posterior disease platform

Bausch + Lomb has acquired the rights to a novel platform technology for treating posterior segment diseases of the eye.

Madison, NJ-Bausch + Lomb has acquired the rights to a novel platform technology for treating posterior segment diseases of the eye.

The new addition to the company’s pipeline already has completed the “proof of principle” research phase. If future trials and commercialization are successful, the drug could reduce the need for ongoing pharmacologic intervention for patients with certain diseases, according to the company.

“Through partnership with leading retinal specialists, we hope to advance this innovative new science . . . to preserve vision in patients suffering from posterior segment conditions,” said Cal Roberts, MD, the company’s chief medical officer.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.